The Ontario government is proposing a rollback of OHIP+, which would restrict the free prescription drug coverage program to dependants under age 25 who aren’t covered by private plans. The previous Liberal government implemented the program in January 2018 with an estimated cost of $465 million annually. It covered all OHIP-insured dependants under age 25 […]
Something interesting happened this month as we examined the 2018 experience of two different plan sponsors in two separate geographies with different demographics. The only similarity between the plans is they both have 80,000 or more individual claimants on their drug plan annually. At the same time last year, we completed a series of predictive analytics on […]
Treating mental health with medications is very different from treating an infection, so why do many people, and many employers, treat them like they’re one and the same? When enhancing communications around wellness programs, plan sponsors should seek innovative ways to support employees with how they use medications and help them understand the interactions between drugs and mental […]
On Dec. 5, the 2018 Face to Face Drug Plan Management Forum in Toronto highlighted the leading issues for plan sponsors to consider in the year ahead, including medical cannabis, pharmacogenetics and drug plan sustainability. Here are some of the highlights of the sessions: A look at the benefits of patient support programs for plan […]
With patient support programs providing a number of benefits for private plan stakeholders, ongoing digitization is likely to allow even greater connectivity and personalization for patients, physicians and payers in the near future. During a panel exploring these initiatives at Benefits Canada‘s Face to Face Drug Plan Management Forum in Toronto on Dec. 5, Sandra Anderson, vice-president of […]
As plan sponsors and private payers begin integrating medical cannabis coverage into benefits plans, it’s crucial they account for the dynamic nature of the industry and remain adaptable to anticipated changes around distribution and product innovation. Although medical cannabis isn’t new, current offerings are just a first step, said Matt Gaudry, director of product support and management at […]
Pharmacogenetic testing can produce significant results for plan members, but it isn’t appropriate for everyone and should never be looked at in isolation, according to a panel discussion at Benefits Canada‘s Face to Face Drug Plan Management Forum. Speaking on the panel in Toronto on Dec. 5, Mark Faiz, chief executive officer of Personalized Prescribing Inc., said […]
With 44 per cent of Canadian workers experiencing mental-health issues and mental health the fastest growing and leading cause of disability claims, benefits plans are feeling the strain. “The numbers are staggering in terms of what we’re seeing and the continual growth of this as an issue,” said Rebecca Smith, director of group life and […]
In its 2018 budget, the federal government created an advisory council on the implementation of national pharmacare, led by former Ontario health minister Eric Hoskins. The council, which solicited submissions from Canadians between June and September, is expected to release its final report in the spring. Whatever the report recommends, Canada is closer to a […]
Spending on prescription drugs is expected to total $33.7 billion in 2018, according to a new report by the Canadian Institute for Health Information. Of that total, $19.3 billion will come from private insurance and individuals paying out of pocket, while the remaining $14.4 billion will be financed by the public sector. As a whole, drug spending […]